Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted) (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$2.39 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 2555.56% to -$2.39 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.73 through Dec 2025, down 1030.3% year-over-year, with the annual reading at -$3.74 for FY2025, 1033.33% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$2.39 in Q4 2025 for Vanda Pharmaceuticals, down from -$0.38 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.17 in Q2 2021 to a low of -$2.39 in Q4 2025.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.17 across 5 years, with a median of -$0.02 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1400.0% in 2021 and later plummeted 3878.18% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.12 in 2021, then grew by 0.0% to $0.12 in 2022, then crashed by 141.67% to -$0.05 in 2023, then tumbled by 80.0% to -$0.09 in 2024, then crashed by 2555.56% to -$2.39 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VNDA at -$2.39 in Q4 2025, -$0.38 in Q3 2025, and -$0.46 in Q2 2025.